Orchard Therapeutics plc Quarterly Nonoperating Income (Expense) in USD from Q1 2018 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Orchard Therapeutics plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2018 to Q3 2023.
  • Orchard Therapeutics plc Nonoperating Income (Expense) for the quarter ending September 30, 2023 was -$12.7M, a 45.1% increase year-over-year.
  • Orchard Therapeutics plc Nonoperating Income (Expense) for the twelve months ending September 30, 2023 was $29M.
  • Orchard Therapeutics plc annual Nonoperating Income (Expense) for 2022 was -$25.9M, a 681% decline from 2021.
  • Orchard Therapeutics plc annual Nonoperating Income (Expense) for 2021 was -$3.32M, a 178% decline from 2020.
  • Orchard Therapeutics plc annual Nonoperating Income (Expense) for 2020 was $4.27M, a 40.8% decline from 2019.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $29M -$12.7M +$10.4M +45.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $18.5M $10.3M +$29M Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$10.5M $8.83M +$15.5M Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 -$25.9M $22.6M +$22.4M +11722% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-14
Q3 2022 -$48.3M -$23.2M -$18.5M -398% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$29.8M -$18.7M -$18.8M -12234% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$11M -$6.66M -$7.65M -772% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$3.32M $191K -$5.15M -96.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 $1.82M -$4.66M -$10.1M -185% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $12M $154K +$773K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $11.2M $991K +$6.91M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.27M $5.34M +$1.6M +42.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 $2.67M $5.47M +$2.99M +121% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$318K -$619K -$3.47M -122% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $3.15M -$5.92M -$4.06M -218% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $7.21M $3.74M -$427K -10.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-02
Q3 2019 $7.64M $2.48M +$1.55M +165% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-03
Q2 2019 $6.09M $2.85M +$753K +35.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $5.34M -$1.86M -$167K -9.85% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $5.51M $4.17M Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 $935K Jul 1, 2018 Sep 30, 2018 6-K 2019-11-07
Q2 2018 $2.1M Apr 1, 2018 Jun 30, 2018 6-K 2019-08-08
Q1 2018 -$1.7M Jan 1, 2018 Mar 31, 2018 6-K 2019-05-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.